Stake Announced Sponsor buyer
Stake in Anagram Therapeutics
Announced 11 May 2026
Advisers
Anagram Therapeutics
Target
Acquirer
Not disclosed
- Target
- Anagram Therapeutics
- Sponsor
- Blackstone Life Sciences
- Target based in
- United States
- Buyer based in
- United States
- Structure
- Minority stake
- Amount raised
- US$250m
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Rare Disease
In the league tables
Similar deals
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- Research Alliance Corporation III and OHB Pediatrics Ltd. d/b/a Oak Hill Bio merger Jul 2026 · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
Sources
- 11 May 2026 Goodwin Advises Anagram Therapeutics on $250 Million Investment from Blackstone Life Sciences goodwinlaw.com
